Alghamdi Mushabab, Somaily Mansour Y, Alemam Shahenda, Majadah Saeed, Hassan Abduaelah Ali H, Meshary Abdullah A, Alasmri Saad Ahmad A, Ali Munif S, Alsubaie Abdullah A, Miskeen Elhadi
Department of Internal Medicine and Rheumatology, College of Medicine, University of Bisha, Bisha, SAU.
Department of Medicine, Rheumatology Division, Armed Forces Hospital - Southern Region, Khamis Mushait, SAU.
Cureus. 2024 Feb 10;16(2):e53992. doi: 10.7759/cureus.53992. eCollection 2024 Feb.
Rheumatoid arthritis (RA) in Saudi Arabia (SA) is a significant health concern with a notable impact on individuals and the healthcare system. This study aimed to investigate the prevalence and profile of comorbidities in patients with RA.
This is a retrospective descriptive study involving 150 RA patients from August 2022 to August 2023, which was conducted at Khamis Mushait General Hospital, a major healthcare institution in SA. We examined the medical records to gather pertinent information. Stata Statistical Software: Release 18 (2023; StataCorp LLC, College Station, Texas, United States) was used for data analysis. The examination focused on sociodemographic factors, disease duration, prescribed medications (including methotrexate and biologic therapy), and the presence of comorbidities. Approval for the study was obtained from the Institutional Review Board of the Aseer Ministry of Health (approval number: H-06-B-091).
The study found a high prevalence of comorbidities in patients with RA. Around 96.7% of the patients had at least one documented comorbidity, highlighting this population's burden of additional health conditions. The most common comorbidity observed was anemia, affecting 48.7% of the patients. Other frequently observed comorbidities include hypertension, hyperlipidemia, diabetes mellitus, osteoporosis, interstitial lung disease, chronic renal disease, stroke, and coronary artery disease. The factors influencing comorbidities included an odds ratio of 1.086 (p=0.025), while being male was associated with lower odds (odds ratio=0.529, p=0.017). Additionally, disease duration (odds ratio=1.164, p=0.007), methotrexate use (odds ratio=2.553, p=0.001), and receiving biologic therapy (odds ratio=3.488, p<0.001) were significant contributors to comorbidities.
These findings highlight the need for comprehensive approaches to address RA and its associated comorbidities. Research and awareness initiatives are essential to understand better the specific nuances of RA in SA, leading to improved diagnostic and treatment strategies for the needs of the local population.
沙特阿拉伯(SA)的类风湿性关节炎(RA)是一个重大的健康问题,对个人和医疗保健系统都有显著影响。本研究旨在调查RA患者中合并症的患病率和概况。
这是一项回顾性描述性研究,于2022年8月至2023年8月对150名RA患者进行,该研究在沙特阿拉伯的主要医疗机构哈米斯穆谢特综合医院进行。我们检查了病历以收集相关信息。使用Stata统计软件:版本18(2023;StataCorp有限责任公司,美国得克萨斯州大学城)进行数据分析。检查重点关注社会人口学因素、疾病持续时间、处方药物(包括甲氨蝶呤和生物疗法)以及合并症的存在情况。该研究获得了阿西尔卫生部机构审查委员会的批准(批准号:H-06-B-091)。
该研究发现RA患者中合并症的患病率很高。约96.7%的患者至少有一种记录在案的合并症,突出了这一人群额外健康状况的负担。观察到的最常见合并症是贫血,影响了48.7%的患者。其他常见的合并症包括高血压、高脂血症、糖尿病、骨质疏松症、间质性肺病、慢性肾病、中风和冠状动脉疾病。影响合并症的因素包括比值比为1.086(p = 0.025),而男性的比值较低(比值比 = 0.529,p = 0.017)。此外,疾病持续时间(比值比 = 1.164,p = 0.007)、甲氨蝶呤的使用(比值比 = 2.553,p = 0.001)和接受生物疗法(比值比 = 3.488,p < 0.001)是合并症的重要促成因素。
这些发现凸显了采用综合方法来应对RA及其相关合并症的必要性。研究和提高认识的举措对于更好地了解沙特阿拉伯RA的具体细微差别至关重要,从而为当地人群的需求制定改进的诊断和治疗策略。